Linden Thomson
Portfolio Manager
About Linden
Linden is the lead manager on the AXA IM Framlington’s Biotech Fund, with two decades of buy-side and sell-side experience as one of the early specialists in the biotechnology sector.
Before joining AXA IM in 2011, Linden worked at Goldman Sachs, where she established a deep technical expertise in the sector and developed the foundation for her framework in company analysis, context and investment Opportunity.
In 2015, Linden was reconised in the ’40 Under 40 Rising Stars of Asset Management’. More recently, she has been a finalist for Fund Manager of the Year in the 'Women In Investment Awards' 2022 & 2023.
Linden holds a Bachelor’s degree in Medical Microbiology from Edinburgh University. She is also a CFA charterholder.
Read Linden's latest articles
Future Trends
Game-changing Alzheimer’s drugs could drive a wave of investment across biotech
- by Linden Thomson
- 14 September 2023 (7 min read)
Future Trends
Why biotech’s history of innovation offers exciting opportunities for investors
- by Linden Thomson,
- 23 February 2022 (7 min read)
Technology
How genetics innovation has expanded biotech investment opportunities
- by Linden Thomson
- 19 June 2023 (7 min read)
Explore more
Stay up to date with the latest market news, investment insights, future trends and our exclusive research.
